This study describes a real-world experience from four patients with NTRK fusion–positive thyroid cancer treated with larotrectinib. The work also reports the frequencies and the types of NTRK gene alterations in thyroid cancer from available public databases and a real-world data set from Tempus.

VIEW THE PUBLICATION